Clinical Trial on Sambazon Acai

A new clinical trial investigating the health benefits of acai, the antioxidant and vitamin-rich berry, is adding to the emerging scientific evidence of the fruit's ability to potentially reduce some metabolic risk factors associated with cardiovascular disease, diabetes and stroke. The latest study won top honors during the Scripps Center for Integrative Medicine on January 23 and revealed promising initial results for using Sambazon acai to improve vascular health, and lower fasting blood sugar levels.

"This pilot study demonstrated the ability of the Sambazon acai pulp product to significantly lower several markers of cardiovascular risk in a relatively short period of time. Given these promising results, and the biologically active components in the acai fruit, further study is merited," said Dr. Jay Udani, MD, CEO and Medical Director of Medicus Research, a leading contract research organization with functional food experience.

Medicus Research recently conducted a pilot study with 10 slightly overweight, but healthy adult male and female participants (representing 1/3 of the American population). Each study participant consumed 100 grams of Sambazon(R) acai frozen fruit pulp twice daily for one month. Researchers measured participants' baseline fasting plasma glucose, plasma insulin levels, lipid levels (total cholesterol, HDL, LDL, triglycerides), high sensitivity C-reactive protein and blood pressure. After 30 days of consuming Sambazon(R) acai, participants' fasting glucose, insulin, total cholesterol, and LDL (bad cholesterol) were significantly reduced, as compared to the baseline. In addition, post-prandial (between meals) increases in blood glucose levels were significantly reduced.

"While additional research is needed, this pilot study suggests that in otherwise healthy, overweight adults, daily consumption of acai reduces several markers of metabolic syndrome associated with an increased risk of diabetes, cardiovascular disease, and stroke," said Jack F. Bukowski, MD, Ph.D., a former Harvard professor and currently Director of the Nutritional Science Research Institute.

This study follows a recently published study showing that acai consumption lowers cholesterol and raises antioxidant activity in rats. Sambazon(R) is committed to scientific and nutritional research about acai and supported the Medicus clinical trial. Sambazon(R) Acai Pure Pulp Packs, which were used in the Medicus study, are a top selling frozen fruit item and available in finer grocery and natural food stores.

Read More